News | Cath Lab | May 13, 2016

New Device Reduces Radiographic Contrast in Patients At Risk of Developing Acute Kidney Injury

SCAI late-breaking study shows Advert device may help avoid acute kidney injury

Osprey Avert

May 13, 2016 — In the largest study of its kind, a new device has been found to significantly reduce the volume of radiographic iodine-based contrast without decreasing image quality in patients who are at risk of developing acute kidney injury (AKI) after undergoing a coronary angiography or percutaneous coronary intervention (PCI). The device — known as Avert — did not, however, reduce contrast-induced AKI (CI-AKI). 

The AVERT study results were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions. 

CI-AKI is the sudden deterioration in renal function that can occur after the administration of contrast media volume (CMV) — during an interventional cardiac procedure. CI-AKI is associated with increased morbidity and mortality, and affects an estimated 20 to 30 percent of patients, particularly those with diabetes or previous renal impairment. Minimizing CMV in patients at risk of AKI is a critical preventative measure.

“Physicians are extremely careful about the volume of dye they administer to patients; the greater the volume, the more problems a physician can encounter,” said Roxana Mehran, M.D., FSCAI, director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and the study’s lead author.

With the Avert system, the operator can control the volume of contrast used during an interventional procedure. Once the appropriate amount of contrast has been injected into the coronary, the remaining dye goes into a reservoir, rather than into the aorta.

The prospective, randomized multi-center study enrolled 578 patients, at 39 sites, who were considered to be at risk of CI-AKI while undergoing coronary angiography with or without PCI. The treatment group (n=292) included hydration and Avert; the control group (n=286) received hydration only. The study’s objectives were to assess total CMV used and determine the incidence of CI-AKI, which was defined as a 0.3 mg/dl increase in serum creatinine within 72 hours post-procedure.

Of the 568 patients with CI-AKI, PCI was performed on 239 (42.2 percent). The use of Avert resulted in a 15.5 percent relative reduction in CMV in all patients (86 ± 51 ml vs. 101 ± 71 ml, p=0.002) and a 22.8 percent relative reduction in CMV for PCI patients (114 ml ± 55 vs. 147 ± 81 ml, p=0.001). There were no significant differences in CI-AKI (27 percent vs. 26.2 percent, p=0.72) or adverse event rates between the two groups.

“The bottom line is the Avert system is safe, easy to use and reduces contrast media volume without sacrificing image quality,” Mehran said. “While the use of this device did not result in a significant reduction of CI-AKI, there was one exception. A post-hoc analysis showed that in certain groups — patients with a GFR between 40-60 — CI-AKI was significantly reduced. The next step would be to study patients with moderate chronic kidney disease in a prospective randomized trial.”

Mehran reported a research grant from Osprey Medical for this study.

For more information: www. SCAI.org/SCAI2016 

Related Content

Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients
News | Heart Failure| May 26, 2017
Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and...
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery| May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
3-D Echo Image Analysis With Philips' HeartModel A.I. is Accurate and Reproducible
News | Cardiovascular Ultrasound| May 24, 2017
May 24, 2017 — Philips recently announced the results from a global study indicating that automated...
Heart Failure Mortality Inversely Related to Wealth of Country
News | Heart Failure| May 24, 2017
Death in patients with heart failure is inversely related to the wealth of the country they live in, according to late...
Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab| May 23, 2017
Shockwave Medical announced last week CE Mark for the company’s Coronary Lithoplasty System for the treatment of...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair| May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
Overlay Init